Financial Ratios Intellego Technologies AB
Equities
INT
SE0016075063
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
39.30 SEK | +0.90% |
|
+2.33% | -3.66% |
Jan. 14 | Sweden's Intellego Technologies Signs Sales, Marketing Rights Deal in US | MT |
Jan. 14 | Intellego CEO Claes Lindahl increases his shareholding | FW |
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Profitability | |||||
Return on Assets | - | 14.12 | -24.67 | -5.37 | 24.63 |
Return on Total Capital | - | 16.55 | -27.53 | -18.85 | 46.78 |
Return On Equity % | - | 122.59 | -37.23 | -54.46 | 72.47 |
Return on Common Equity | - | 122.59 | -37.23 | -54.46 | 72.47 |
Margin Analysis | |||||
Gross Profit Margin % | 68.74 | 86.05 | 87.18 | 52.48 | 82.1 |
SG&A Margin | 414.61 | 70.03 | 142.82 | 56.81 | 36.39 |
EBITDA Margin % | -342.82 | 14.63 | -52.14 | -3.31 | 45.14 |
EBITA Margin % | -372.32 | 11.72 | -52.18 | -4.9 | 44.01 |
EBIT Margin % | -372.32 | 11.72 | -52.18 | -14.69 | 43.96 |
Income From Continuing Operations Margin % | -374.64 | 42.6 | -41.68 | -16.82 | 31.52 |
Net Income Margin % | -374.64 | 42.6 | -41.68 | -16.82 | 31.52 |
Net Avail. For Common Margin % | -374.64 | 42.6 | -41.68 | -16.82 | 31.52 |
Normalized Net Income Margin | -234.15 | 7.24 | -33.08 | -12.17 | 22.75 |
Levered Free Cash Flow Margin | - | 3.75 | -74.11 | 103.07 | -60.55 |
Unlevered Free Cash Flow Margin | - | 3.84 | -73.65 | 106.06 | -58.92 |
Asset Turnover | |||||
Asset Turnover | - | 1.93 | 0.76 | 0.58 | 0.9 |
Fixed Assets Turnover | - | - | 136.64 | 18.47 | 7.35 |
Receivables Turnover (Average Receivables) | - | 29.52 | 5.1 | 9.65 | 3.74 |
Inventory Turnover (Average Inventory) | - | 1.9 | 1.02 | 4.53 | 2.25 |
Short Term Liquidity | |||||
Current Ratio | 5.44 | 3.23 | 6.73 | 0.8 | 2.43 |
Quick Ratio | 4.1 | 2.52 | 5.79 | 0.69 | 2.04 |
Operating Cash Flow to Current Liabilities | -6.92 | 0.87 | -3.98 | 0.02 | -0.37 |
Days Sales Outstanding (Average Receivables) | - | 12.4 | 71.53 | 37.82 | 97.58 |
Days Outstanding Inventory (Average Inventory) | - | 193.08 | 358.26 | 80.59 | 162.41 |
Average Days Payable Outstanding | - | 83.24 | 113.14 | 21.02 | 81.92 |
Cash Conversion Cycle (Average Days) | - | 122.24 | 316.65 | 97.39 | 178.08 |
Long Term Solvency | |||||
Total Debt/Equity | 77.95 | 15.58 | 3.33 | 104.61 | 20.25 |
Total Debt / Total Capital | 43.81 | 13.48 | 3.23 | 51.13 | 16.84 |
LT Debt/Equity | 66.95 | 13.02 | 0.86 | 82.03 | 14.18 |
Long-Term Debt / Total Capital | 37.62 | 11.27 | 0.84 | 40.09 | 11.79 |
Total Liabilities / Total Assets | 51.12 | 26.69 | 11.83 | 89.29 | 40.28 |
EBIT / Interest Expense | -160.17 | 81.85 | -69.54 | -3.08 | 16.92 |
EBITDA / Interest Expense | -147.48 | 102.15 | -69.49 | -0.69 | 17.64 |
(EBITDA - Capex) / Interest Expense | -147.48 | 100.79 | -71.05 | -0.74 | 12.31 |
Total Debt / EBITDA | -0.3 | 0.6 | -0.11 | -10.5 | 0.35 |
Net Debt / EBITDA | 0.26 | -1.19 | 1.66 | 12.37 | 0.26 |
Total Debt / (EBITDA - Capex) | -0.3 | 0.61 | -0.11 | -9.79 | 0.51 |
Net Debt / (EBITDA - Capex) | 0.26 | -1.21 | 1.63 | 11.54 | 0.37 |
Growth Over Prior Year | |||||
Total Revenues, 1 Yr. Growth % | - | 915.03 | 23.55 | 523.04 | 219.26 |
Gross Profit, 1 Yr. Growth % | - | 1.17K | 25.16 | 275.06 | 399.46 |
EBITDA, 1 Yr. Growth % | - | -143.3 | -540.47 | -60.51 | -910.94 |
EBITA, 1 Yr. Growth % | - | -131.95 | -650.09 | -41.46 | -835.56 |
EBIT, 1 Yr. Growth % | - | -131.95 | -650.09 | 75.45 | -830.7 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | -215.43 | -220.86 | 151.46 | -493.56 |
Net Income, 1 Yr. Growth % | - | -215.43 | -220.86 | 151.46 | -493.56 |
Normalized Net Income, 1 Yr. Growth % | - | -131.37 | -664.9 | 129.13 | -510.63 |
Diluted EPS Before Extra, 1 Yr. Growth % | - | - | -196.39 | 150.3 | -411.88 |
Accounts Receivable, 1 Yr. Growth % | - | 400.99 | 657.61 | 172.91 | 925.56 |
Inventory, 1 Yr. Growth % | - | 22.83 | 183.4 | 502.76 | 82.6 |
Net Property, Plant and Equip., 1 Yr. Growth % | - | - | 729.43 | 4.96K | 180.19 |
Total Assets, 1 Yr. Growth % | - | 186.48 | 224.75 | 854.51 | 50.11 |
Tangible Book Value, 1 Yr. Growth % | - | 329.62 | 290.6 | -528.23 | -226.17 |
Common Equity, 1 Yr. Growth % | - | 329.62 | 290.6 | 15.92 | 1.04K |
Cash From Operations, 1 Yr. Growth % | - | -133.62 | -1.06K | -125.76 | -744.61 |
Capital Expenditures, 1 Yr. Growth % | - | - | 643.3 | 27.17 | 18.48K |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | -2.54K | -966.48 | -304.23 |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | -2.47K | -997.23 | -297.53 |
Compound Annual Growth Rate Over Two Years | |||||
Total Revenues, 2 Yr. CAGR % | - | - | 254.13 | 177.45 | 346 |
Gross Profit, 2 Yr. CAGR % | - | - | 298.8 | 116.66 | 332.81 |
EBITDA, 2 Yr. CAGR % | - | - | 38.11 | 31.9 | 314.95 |
EBITA, 2 Yr. CAGR % | - | - | 32.58 | 79.46 | 309.58 |
EBIT, 2 Yr. CAGR % | - | - | 32.58 | 210.66 | 309.38 |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | 18.12 | 74.34 | 287.88 |
Net Income, 2 Yr. CAGR % | - | - | 18.12 | 74.34 | 287.88 |
Normalized Net Income, 2 Yr. CAGR % | - | - | 33.11 | 259.77 | 269.87 |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | - | 55.32 | 238.16 |
Accounts Receivable, 2 Yr. CAGR % | - | - | 516.08 | 354.71 | 429.03 |
Inventory, 2 Yr. CAGR % | - | - | 86.58 | 313.31 | 231.75 |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | - | 1.95K | 1.65K |
Total Assets, 2 Yr. CAGR % | - | - | 205.01 | 456.76 | 262.98 |
Tangible Book Value, 2 Yr. CAGR % | - | - | 309.64 | 308.98 | 110.11 |
Common Equity, 2 Yr. CAGR % | - | - | 309.64 | 112.78 | 198.74 |
Cash From Operations, 2 Yr. CAGR % | - | - | 79.41 | 57.06 | 54.28 |
Capital Expenditures, 2 Yr. CAGR % | - | - | - | 207.45 | 1.43K |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 1.36K | 303.11 |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 1.36K | 298.93 |
Compound Annual Growth Rate Over Three Years | |||||
Total Revenues, 3 Yr. CAGR % | - | - | - | 327.51 | 190.74 |
Gross Profit, 3 Yr. CAGR % | - | - | - | 290.72 | 186.21 |
EBITDA, 3 Yr. CAGR % | - | - | - | -9.01 | 323.29 |
EBITA, 3 Yr. CAGR % | - | - | - | 0.96 | 351.89 |
EBIT, 3 Yr. CAGR % | - | - | - | 45.55 | 351.74 |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | - | 51.95 | 162.96 |
Net Income, 3 Yr. CAGR % | - | - | - | 51.95 | 162.96 |
Normalized Net Income, 3 Yr. CAGR % | - | - | - | 59.53 | 325.95 |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | - | 122.55 |
Accounts Receivable, 3 Yr. CAGR % | - | - | - | 369.64 | 496.31 |
Inventory, 3 Yr. CAGR % | - | - | - | 175.82 | 214.78 |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | - | - | 1.26K |
Total Assets, 3 Yr. CAGR % | - | - | - | 346.14 | 249.76 |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | 315.75 | 158.35 |
Common Equity, 3 Yr. CAGR % | - | - | - | 168.94 | 226.67 |
Cash From Operations, 3 Yr. CAGR % | - | - | - | -6.05 | 183.52 |
Capital Expenditures, 3 Yr. CAGR % | - | - | - | - | 1.11K |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | 635.06 |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | 622.71 |
- Stock Market
- Equities
- INT Stock
- Financials Intellego Technologies AB
- Financial Ratios